IGI Logo

Zydus Lifesciences is currently trading at Rs. 477.80, up by 1.80 points or 0.38% from its previous closing of Rs. 476.00 on the BSE.

The scrip opened at Rs. 474.05 and has touched a high and low of Rs. 478.25 and Rs. 473.05 respectively. So far 3309 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.

Last one week high and low of the scrip stood at Rs. 479.40 and Rs. 463.35 respectively. The current market cap of the company is Rs. 48180.92 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 16.21% and 8.81% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Lenalidomide Capsules, 2.5 mg and 20 mg (USRLD: Revlimid Capsules). Lenalidomide Capsules are used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. The products will be launched in the US market shortly.

The drugs will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad (India). Lenalidomide Capsules had annual sales of $183 million in the United States (IQVIA MAT Dec. 2022). The group now has 349 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.